Back to Search
Start Over
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.
- Source :
-
Journal of neurovirology [J Neurovirol] 2017 Apr; Vol. 23 (2), pp. 260-272. Date of Electronic Publication: 2016 Nov 28. - Publication Year :
- 2017
-
Abstract
- The human immunodeficiency virus (HIV), hepatitis C virus (HCV), and the treatment of HCV with pegylated interferon and ribavirin (IFN/RBV) have been associated with neurocognitive and psychiatric abnormalities. The goal of this research was to prospectively evaluate neurocognitive functioning among a group of HCV mono-infected and HIV/HCV co-infected patients during the first 24 weeks of IFN/RBV treatment while accounting for practice effects, normal variations in change over time, and variations in IFN/RBV treatment exposure. Forty-four HCV mono-infected and 30 HIV/HCV co-infected patients were enrolled in a prospective study of patients beginning on IFN/RBV for chronic HCV infection. Patients were administered a depression inventory, a measure of fatigue, a structured psychiatric interview, and a neurocognitive battery at baseline and 24 weeks after initiation of treatment. Analyses were conducted to explore possible associations between neurocognitive functioning and the following: HIV/HCV co-infection vs. HCV mono-infection, IFN and RBV treatment exposure, psychiatric status, liver disease stage, and other medical characteristics. At baseline, there were no significant differences between the two groups' neuropsychiatric or neurocognitive function other than the mono-infected group had significantly higher reports of fatigue (p = 0.033). Over the course of 24 weeks of treatment after controlling for practice effects, the HIV/HCV co-infected patients experienced significantly greater declines in memory (t(56) = 2.14, p = 0.037) and global neurocognitive functioning (t(53) = 2.28, p = 0.027). In a well-characterized sample of mono-infected and co-infected patients, it appears that persons with HIV/HCV co-infection are potentially more vulnerable to neurocognitive sequalae during HCV treatment.
- Subjects :
- Adult
Aged
Cognitive Dysfunction complications
Cognitive Dysfunction drug therapy
Cognitive Dysfunction virology
Coinfection
Drug Therapy, Combination
Female
HIV pathogenicity
HIV physiology
HIV Infections complications
HIV Infections drug therapy
HIV Infections virology
Hepacivirus drug effects
Hepacivirus pathogenicity
Hepacivirus physiology
Hepatitis C, Chronic complications
Hepatitis C, Chronic drug therapy
Hepatitis C, Chronic virology
Humans
Male
Middle Aged
Neuropsychological Tests
Prospective Studies
Recombinant Proteins therapeutic use
Antiviral Agents therapeutic use
Cognitive Dysfunction physiopathology
HIV Infections physiopathology
Hepatitis C, Chronic physiopathology
Interferon-alpha therapeutic use
Polyethylene Glycols therapeutic use
Ribavirin therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1538-2443
- Volume :
- 23
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of neurovirology
- Publication Type :
- Academic Journal
- Accession number :
- 27896573
- Full Text :
- https://doi.org/10.1007/s13365-016-0494-8